Sorrento To Present At The 2014 Oppenheimer Healthcare Conference.
SAN DIEGO, Dec. 3, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, today announced that Dr. Henry Ji, President and Chief Executive Officer, will present at the 2014 Oppenheimer Healthcare Conference on Thursday, December 11, 2014 at 2:45 pm ET in the Act I Room at the Crowne Plaza Hotel in New York City.
About Sorrento Therapeutics, Inc.E[sz]
Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento's most advanced asset Cynviloqe, the next-generation nanoparticle paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento's strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bi-specific therapeutic antibodies, and ADCs.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sorrento-to-present-at-the-2014-oppenheimer-healthcare-conference-300003803.html</a>
SOURCE Sorrento Therapeutics, Inc.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Conference news|
|Date:||Dec 3, 2014|
|Previous Article:||Zacks Investment Ideas feature highlights: JPMorgan Alerian MLP Index ETN, UBS ETRACS Alerian MLP Infrastructure ETN and Credit Suisse Cushing 30 MLP...|
|Next Article:||Launch of TCS BaNCS Digital Platform to Help Banks Deliver Hyper-connected, Personalized Experience to Customers.|